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Abstract
Background: Recently promising trials of innovative biomedical approaches to prevent HIV transmission have been
reported. Participants’ non-adherence to the prevention methods complicates the analyses and interpretation of trial
results. The influence of variable sexual behaviors within and between participants of trials further obscures matters. Current
methodological and statistical approaches in HIV-prevention studies, as well as ongoing debates on contradictory trial
results, may fail to accurately address these topics.
Methodology/Principal Findings: Through developing a cumulative probability model of infection within HIV prevention
trials, we demonstrate how adherence and sexual behavior patterns impact the overall estimate of effectiveness, the
effectiveness of prevention methods as a function of adherence, and conclusions about methods’ true effectiveness.
Applying the model to summary-level data from the CAPRISA trial, we observe markedly different values for the true
method effectiveness of the microbicide, and show that if the gel would have been tested among women with slightly
different sexual behavior patterns, conclusions might well have been that the gel is not effective.
Conclusions/Significance: Relative risk and adherence analyses in HIV prevention trials overlook the complex interplay
between adherence and sexual behavior patterns. Consequently, they may not provide accurate estimates of use- and
method-effectiveness. Moreover, trial conclusions are contingent upon the predominant sexual behavior pattern of
participants and cannot be directly generalized to other contexts. We recommend researchers to (re)examine their data and
use the cumulative probability model to estimate the true method effectiveness, which might contribute to resolving
current questions about contradictory trial results. Moreover, we suggest taking into account the issues raised in the design
of future trials and in population models estimating the impact of large-scale dissemination of prevention methods.
Comprehension of the topics described will help readers to better interpret (apparently contradictory) trial outcomes.
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Introduction
Despite recent indications that the spread of HIV is declining in
several parts of the world, HIV remains one of the most severe
pandemics in human history, with an estimated 33.3 million
people currently living with the disease [1]. New approaches to
prevent HIV transmission can therefore have an impact on the
lives of millions. Major efforts have been directed at the
identification of safe and effective pre-exposure prophylaxes
(PrEP), with alternately spectacular and disappointing results in
recent years [2,3,4,5]. The results from the CAPRISA 004 trial
reported by Karim and colleagues in the summer of 2010 were a
breakthrough, since it was the first trial to show that antiretroviral
microbicides can be a promising new tool for HIV-prevention [3].
Specifically, the CAPRISA team observed a 39% lower HIV
incidence rate among women receiving a vaginal tenofovir gel
compared to those receiving a placebo, a statistically significant
and clinically meaningful effect.
A series of prior studies had failed to show a protective effect of
microbicides [6,7]. However, as Weiss and colleagues (2008) have
pointed out, not finding an effect does not necessarily imply that
the microbicide studied is not efficacious [8]. Inconsistent or
incorrect use of microbicides is a common problem, with an
estimated 30% of coital acts not being covered by the use of the gel
[7]. Clearly, more consistent use of PrEP should result in better
preventive effects if the method is in fact protective. This is exactly
what the CAPRISA team observed in their study, where high
adherers (i.e., women who used the gel in .80% of the sexual
encounters) had a 54% lower HIV-incidence compared to 38% for
medium (50–80% gel use) and 28% for low adherers (,50% gel
use) [3]. Such adherence analyses are essential, since they can
reveal the true method effectiveness, information that is vital for
directing future research efforts (i.e., do better microbicides need
to be developed or should efforts be directed at designing effective
adherence interventions and efficient gel dissemination strategies?).
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Although PrEP trials have paid attention to the role of
adherence, and even though the variable effectiveness of the
tenofovir gel in the CAPRISA trial was found to be related to
participants’ adherence in the expected direction, the studies
conducted so far seem to suffer from several important method-
ological and statistical limitations. Consequently, trials may have
suggested that a PrEP is not effective when in fact it is, or may
have produced incorrect estimates of the effectiveness of PrEP
under variable adherence conditions. In this paper, we describe
these concerns, using the CAPRISA trial as an illustration, and
discuss a framework for including adherence and other potential
effect modifiers in a more meaningful manner in the analyses.
Through mathematical modeling, we demonstrate that applying
this framework may result in markedly different conclusions about
the overall treatment effectiveness, the effectiveness under variable
adherence levels, as well as the true method effectiveness of the
prevention method tested. Although some of the issues discussed
will need to be addressed in future research, we recommend that
authors of previous PrEP trials to re-examine their primary and
adherence-related analyses.
For the purpose of clarity in terminology and an illustration
based on CAPRISA data, we will focus on vaginal microbicide
studies hereafter and return to PrEP trials in general in the
Discussion.
Making Sense of Adherence Percentages
In this section, we describe the concept of adherence and then
discuss several issues when trying to relate adherence to an HIV
prevention method to absolute HIV infection risk. In the next
section, we explain and demonstrate how these issues also impact
relative risks of infection in double-blind, placebo controlled HIV
prevention trials.
In the context of medication studies, adherence has been
defined as ‘‘the extent to which patients’ actual history of drug
administration corresponds to the prescribed regimen’’ [9].
Adherence is usually computed by dividing the number of
medication doses taken (or taken within the prescribed time
interval; the numerator) by the number of doses prescribed (the
denominator), multiplied by 100 to arrive at an adherence
percentage [10]. Hence, when two patients are prescribed a
once-daily regimen and have 70% adherence after 100 days, it
means that both patients have omitted the taking of 30 pills.
Assuming that other potential treatment effect modifiers are
comparable between patients (e.g., pharmacokinetics and phar-
macodynamics; cf. [11,12]) and that patterns of missed doses are
similar, 70% adherence is then considered to represent a similar
absolute risk of disease progression for both patients (i.e., 30 days
without therapeutic coverage). An important assumption under-
lying this adherence percentage is that each day without
therapeutic coverage entails the same risk of disease progression
(i.e., missing a pill on Sunday encompasses the same risk as missing
a pill on Tuesday). In medication adherence studies, the main
challenge in studying this topic is the accurate measurement of
patients’ pill intake behavior over time and analysis of the impact
of different adherence patterns [11].
In microbicide trials the situation is considerably more complex.
Typically adherence is computed by dividing the number of gel
applicators used over a certain time period (e.g., 1 month) by the
number of coital acts during that period. Hence, first, researchers
need to obtain reliable data on both the numerator (the number of
gel applicators used correctly) and the denominator (the number of
coital acts). There are well-recognized challenges related to the
reliable measurement of such intimate data on which others have
written excellent work [13,14,15,16].
Second, current computations of adherence percentages in
microbicide trials are based on the assumption that each sexual
encounter entails the same risk of obtaining HIV. However,
although a reliable behavioral proxy for HIV infection has not yet
been established [17], it is known that infection risk depends on a
variety of factors including the type of sexual practice [18],
whether condoms were used [19], whether the male partner is
circumcised [20,21], and the presence of other sexually transmit-
ted diseases (e.g., [22]). Since, depending on these parameters, the
riskiness of a sexual encounter can vary considerably, adherence
can only be meaningfully incorporated into the analysis if one
treats gel use over the set of sexual encounters that comprise risky
behaviors differently than gel use over (non- or) less-risky
encounters.
The third issue pertains to the fact that similar adherence
percentages in HIV prevention trials do not represent the same
degree of riskiness for different people. Whereas 70% adherence
represents 30 days without therapeutic coverage for patients using
a once-daily pill regimen for 100 days, in HIV prevention studies
some women may have had 10 sexual encounters while others
may have had 100. So what then does, for example, 70% gel
adherence imply in terms of potential risk reduction by using the
gel? For women who had 10 sexual encounters, it meant having
approximately 3 events ‘‘without gel coverage’’. For women who
had 100 sexual encounters, it meant having 30 events without the
protection of the gel. In other words, the adherence percentage
does not represent the same absolute risk across different risk
behavior patterns (i.e., between women or within women over
time).
Fourth, an additional element that must be considered in the
context of microbicide trials is how the number of (high- and low-
risk) contacts are distributed over a given number of partners. In
particular, the risk of HIV infection differs whether a woman has
100 contacts with a single partner, 10 contacts with 10 different
partners, or one contact with 100 different partners [23].
Therefore, when analyzing the influence of adherence, one must
not only account for the riskiness of the contacts and the total
number of contacts, but also for the number of partners that the
women have intercourse with during the course of the trial.
Finally, HIV-prevention trials can take several years to
complete, with end points for participants being either an HIV
infection during the study or no seroconversion at the end of the
study. HIV-tests are typically conducted every 1–3 months in these
trials. Therefore, researchers can estimate the time window in
which the HIV infection must have occurred (e.g., the previous
3 months). Since sexual behavior and adherence may vary over
time and patients may stop using the gel periodically or even
completely (which is also common within medication trials; see
Blaschke et al., 2012) [11], capturing the relevant risk behaviors
and data on gel adherence over these time periods, as compared
with the time periods that did not lead to seroconversion, should
provide considerably more accurate estimates of HIV-risk
behavior patterns and (non)adherence, and thus the effectiveness
of the gel under variable adherence conditions. At present, studies
typically use the average or median score over the whole study
period for some parameters (e.g., adherence) and baseline values
for others (e.g., number of partners in the past month).
From Absolute to Relative Risks
We assume that two of the issues discussed above, namely the
need for reliable measurements and the summarizing of these data
in meaningful time-windows preceding HIV-tests, speak for
themselves. What is less evident, however, is that behaviors that
affect the absolute infection risk (i.e., the riskiness of sexual
Effectiveness of HIV Prevention Methods
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encounters, the frequency of these encounters, the number of
partners) can also affect relative risks, since randomization in HIV-
prevention trials should lead to such behavior patterns being
equally distributed over the treatment and placebo conditions.
First, consider the point that, in order to obtain an accurate
estimate of the relation between adherence and the relative risk on
becoming infected, one needs to control for the total number of
risky encounters over which adherence has been computed. We
will illustrate this point using a cumulative probability (or
Bernoulli-process) model of HIV infection [23–26]. The cumula-
tive probability model is a simple mathematical model based on
the rules of probability that describes how the probability of
infection accumulates when risk factors, such as number of
contacts or the number of partners, increase. An overview of the
mathematical symbols and their meaning used throughout this
paper is provided in Table 1.
Let a denote the per-contact probability of an HIV infection for
a single unprotected (i.e., without condoms) encounter with an
HIV-positive partner. Then the cumulative risk of infection for a
total of n unprotected contacts with an HIV-positive partner for
women in the control group is obtained by subtracting the risk of
never becoming infected in any of the n contacts (i.e., (1{a)n)
from 1, yielding
PC~1{(1{a)
n,
the probability of seroconversion in one of the n encounters.
For women in the treatment group, the per-contact risk of
infection is reduced by a certain amount when using the gel. We
will let ha denote this reduced per-contact infection risk, so that h
reflects the true relative risk (i.e., the gel’s true effectiveness for
reducing the per-contact infection risk). Moreover, let ln denote
the proportion of encounters unprotected by condoms where the
gel is used. Then the cumulative risk of infection in the treatment
group is given by subtracting the product of the probabilities of not
becoming infected on any of the occasions where the gel was used
(i.e., (1{ha)lnn) and where it was not used (i.e., (1{a)(1{ln)n)
from 1, yielding
PT~1{(1{ha)
lnn(1{a)(1{ln)n:
Figure 1 displays the relation between the number of sexual
encounters without condoms (on the x-axis) and the cumulative
risk of infection for control participants (top line) and intervention
participants with 50% and 100% adherence (middle and bottom
line, respectively) on the y-axis, assuming a per-contact infection
risk of a~0:003 (based on the recent meta-analysis by Boily, 2009)
[18] and an assumed efficacy of a microbicide gel of 50% (i.e.,
h~0:50). The figure inset shows a close-up for small n. In addition,
the relative infection risk, RR~PT=PC , is indicated when
comparing women in the treatment group with women in the
control group for a given number of n and assuming either 50% or
100% adherence.
As can be seen, with only 1 unsafe contact during which the gel
was used, the relative risk of infection in the treatment group is
0.50 (i.e., the gel’s true effectiveness). With an increasing number
of contacts, the infection risk increases non-linearly, with a relative
risk of 0.54 after 100 encounters for 100% adherence and a
relative risk of 0.78 for 50% adherence. As the number of risky
contacts increases further (the range used is larger than what is
typically observed in a trial, however, it is not unrealistic from a
life-time perspective), the absolute infection risk in all groups
approaches 1 and so does the relative risk. Therefore, Figure 1
shows that coital frequency has a direct impact on the cumulative
relative risk, regardless of the level of adherence (i.e., the apparent
effectiveness of the gel decreases with increasing coital frequency).
Moreover, the impact of adherence on the relative risk (i.e., the
difference in the relative risk for 50% and 100% adherence) also
depends on whether one focuses on women with 1, 100, 400, or
800 contacts. For example, for 100 contacts, 50% adherence
implies a 0.78/0.54= 1.44 times higher infection risk than 100%
adherence. However, for 400 contacts, the difference between
50% and 100% adherence is smaller, leading to a 0.85/
0.65= 1.31 times higher risk of infection. Figure 1 thus shows
how both the cumulative relative risk as well as the relation
between adherence and relative risk, due to the accumulation of
risk over time in both groups, depends non-linearly on the number
of risky contacts.
Table 1. Symbols and abbreviations used in the cumulative probability model and their interpretation.
Symbol Interpretation
a per-contact HIV infection probability for a single unprotected (i.e., without condoms) sexual encounter with an HIV-positive partner
h per-contact relative HIV infection probability for a single unprotected (i.e., without condoms) sexual encounter with an HIV-positive partner
when using the gel (therefore ha reflects the per-contact risk of infection when using the gel)
n number of unprotected (i.e., without condoms) encounters (per partner)
ln proportion of unprotected (i.e., without condoms) encounters where the gel is used
k number of protected (i.e., with condoms) encounters (per partner)
lk proportion of protected (i.e., with condoms) encounters where the gel is used
e probability of a condom failing to provide proper protection
p prevalence of HIV in the population
m number of partners
PC cumulative risk of infection in the control group implied by the model based on the behavioral pattern of the women
PT cumulative risk of infection in the intervention group implied by the model based on the behavioral pattern of the women
RR = PT /PC cumulative relative risk of infection implied by the model for women in the intervention group compared to women in the control group
doi:10.1371/journal.pone.0044029.t001
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Second, consider the point that, in order to obtain an accurate
estimate of the relation between adherence and the relative risk of
becoming infected, one needs to control for behaviors that can
impact the per-contact infection risk. In microbicide trials, the
most important (i.e., most common and protective) behavior
among sexually active women, on which data is also typically
collected, is condom use. Let k denote the number of condom-
protected contacts and the chance of a condom failing to provide
proper protection (e.g., due to incorrect use, slippage, or
breakage). We will assume a value of "~0:20 based on the results
from a meta-analysis on condom effectiveness for reducing HIV
transmission [19]. The cumulative risk of infection in the control
and treatment group when always using condoms is then given by
PC~1{(1{ea)
k
and
PT~1{(1{hea)
lkk(1{ea)(1{lk )k,
respectively, where lk now denotes the proportion of condom-
protected encounters where the gel is used. For a single encounter,
the relative infection risk is then again equal to h~0:50. However,
since the infection risk now accumulates more slowly as the
number of condom-protected contacts increases (i.e., the 3 lines in
Figure 1 would have much flatter slopes), relative infection risks
can be markedly different for women using condoms and not using
condoms, despite similar adherence levels and number of sexual
encounters. For example, for 400 encounters protected by
condoms, the relative risk is now equal to RR100%~0:53 for
100% adherence and RR50%~0:77 for 50% adherence. Not only
do these relative risks differ from those we found earlier for the
same number unprotected encounters (i.e., RR100%~0:65 and
RR50%~0:85; see Figure 1), but the ratio of these relative risks also
differs (i.e., 50% adherence implies a 0.85/0.65= 1.31 times
higher risk of infection compared to 100% adherence for 400
unprotected contacts; the same number of protected contacts
implies that 50% adherence is 0.77/0.53 = 1.45 times more risky).
Consequently, not only the number of contacts, but also the
riskiness of the contacts must be considered when interpreting the
cumulative relative risk and when examining the influence of
adherence on the relative risk of infection. In practice, this could
be accomplished by calculating separate adherence percentages
for unprotected and protected contacts.
Besides the total number of contacts and the riskiness of the
contacts, a third factor to consider is the number of partners. For
this, the actual prevalence of HIV in the population (in this case,
the population of men with whom women may have sexual
contacts) needs to be incorporated into the computations. Based
on recent UNAIDS figures [1], we will assume a prevalence of
20% (i.e., p~0:20) to represent a high prevalence region in Sub-
Saharan Africa. Now consider women in the control group who
Figure 1. Cumulative risk of infection as a function of the number of unprotected contacts (n) with an HIV-infected partner for
women in the control and treatment group for different levels of adherence to the intervention gel (RR100% and
RR50% indicate the relative risk of infection for 100% and 50% adherence to the gel).
doi:10.1371/journal.pone.0044029.g001
Effectiveness of HIV Prevention Methods
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e44029
have n unprotected contacts per partner with a total of m different
partners (for a total of n|m unprotected contacts). Based on the
cumulative probability model of HIV infection, their infection risk
is given by
PC~1{f1{p½1{(1{a)ngm,
where p½1{(1{a)n is the joint probability that a particular
partner is HIV-positive and the risk that seroconversion occurs in
at least one of the n unprotected contacts with that partner (hence
1{p½1{(1{a)n is the probability that no seroconversion occurs
with that partner) and f1{p½1{(1{a)ngm denotes the proba-
bility of no seroconversion with any of the m partners. On the
other hand, for women in the treatment group, the cumulative risk
is equal to
PT~1{f1{p½1{(1{ha)lnn(1{a)(1{ln)ngm,
which incorporates the reduced per-contact infection risk for
encounters where the gel is actually used.
Several important points can be illustrated based on these
equations. First, for a given number of total contacts, the absolute
infection risk increases as the number of partners increases. For
example, while 400 unprotected contacts with a single partner
implies a 0.14 risk of infection for women in the control group, 40
contacts per partner with a total of 10 different partners implies a
cumulative risk of 0.21. Therefore, all else equal, a higher number
of partners increases one’s risk of being exposed to HIV and hence
one’s risk of becoming infected (see also [17]). Second, the relative
infection risk between intervention and control participants also
depends on the number of partners. For example, assuming that
the women in the treatment group are 100% adherent, the relative
risk is 0.65 for women with 400 unprotected contacts with a single
partner while 40 contacts per partner with a total of 10 partners
yields a relative risk of 0.54. Hence, the differences in absolute
infection risk carry over to the relative risk. Finally, also the impact
of adherence on the relative risk depends on the number of
partners. For example, for 50% (instead of 100%) adherence, the
relative risks for the two behavior patterns described above are
0.85 and 0.78, respectively. Therefore, while the relative risk of
infection is 0.85/0.65= 1.31 times greater for 50% as opposed to
100% adherence for women with 400 contacts with a single
partner, the relative risk is 0.78/0.54= 1.44 times greater for
women who have 40 contacts with 10 partners each.
In HIV prevention trials, the factors discussed above all act
simultaneously. However, although microbicide trials tend to
collect data on adherence, number of partners, coital frequency,
condom use, and sometimes on gel adherence over condom and
non-condom use events separately, neither their overall analyses of
the relative risk nor any secondary adherence analyses take these
factors into account. Our modeling suggests, however, that this has
most likely resulted in incorrect estimates of the overall treatment
effectiveness, the effectiveness of gels under different adherence
levels, as well as the true method effectiveness of microbicides.
In the next section, a cumulative probability model is described
that incorporates all these different elements. This model can be
used with aggregate or individual-level trial data to evaluate the
effectiveness of a biomedical prevention measure that does
consider these potentially important effect modifiers. We use the
model to illustrate (a) how the true method effectiveness of
prevention measures can be estimated while taking variable risk
behavior patterns into account, (b) the impact of different
behavioral risk patterns on conclusions about treatment effective-
ness under variable adherence conditions, and (c) how different,
plausible behavioral patterns in the study population can lead to
very different conclusions about overall treatment effectiveness.
We will use data from the CAPRISA trial to illustrate these points.
Integrated Cumulative Model and Application to the
CAPRISA Trial
In a typical microbicide trial, women are randomly assigned to
either the actual treatment group or a placebo condition. At
regular intervals (e.g., once per month), the number of sexual
partners, the number of sexual contacts per partner, condom
usage, and gel adherence are assessed. For the sake of the
argument, we assume that these measurements are reliable and
valid. As above, m denotes the total number of partners for a
particular woman over the entire study period, n the number of
sexual encounters per partner without the protection of condoms,
and k the number of encounters with condoms (note that for
simplicity, we assume that n and k are the same for each partner,
although one could easily extend the calculations to situations
where this assumption does not hold. The main conclusions,
however, would remain unchanged). All of these variables exert an
influence on the risk of infection, which accumulates with
increasing values of m, n, and k. The particular combination of
m, n, and k denotes a certain behavior pattern (e.g., monogamy,
polygamy).
For women in the control group, the cumulative risk of infection
for a particular behavior pattern is then given by
PC~1{f1{p½1{(1{a)n(1{ea)kgm:
Applying this model to the CAPRISA trial requires obtaining
sample-specific data, since HIV prevalence, coital frequency,
condom use, and number of partners can vary considerably
between regions and populations. Table 2 lists the values that were
used for the various variables in the model. The source and/or
derivation of these values is discussed in the remainder of this
section.
Recent figures indicate that, of all regions in South Africa, HIV
prevalence rates are among the highest in the KwaZulu-Natal
province, where the trial was conducted [27]. For adult resident
Table 2. Values used for the cumulative probability model for
the CAPRISA trial.
Variable Value
a 0.015
h 0.32
n 9
ln 0.44
k 36
lk 0.78
e 0.20
p 0.32
m 2
PC 0.134
PT 0.085
doi:10.1371/journal.pone.0044029.t002
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males in the age range of 20–39, Welz and colleagues (2007)
observed a prevalence of 32%, so we set p~0:32 [28]. As before,
we assume that the chance of a condom failing is e~0:20. On
average, women in the CAPRISA trial had 90 sex acts, 18 without
condoms (i.e., risky contacts) and 72 with (i.e., less-risky contacts)
[3]. Based on the baseline CAPRISA data, we assume that the
women had on average m~2 partners during the 18 months,
which corresponds to an average of n~9 contacts per partner
without condoms and k~36 contacts with condoms (note that in
sensitivity analyses the conclusions remained unchanged when
changing the number of partners to 1, 3, or 4). Using these
numbers in the equation above and setting the per-contact
infection risk to a~0:015, we obtain an average cumulative risk of
PC~1{f1{0:32½1{(1{0:015)9(1{0:20|0:015)36g2~0:134
(corresponding closely to the 60 HIV infections observed among
the 444 women in the placebo group). The value of a used here is
quite high (cf. [18,29]), but so was the infection risk observed in the
control group (i.e., 9.1 cases per 100 woman-years) despite low
levels of reported sexual risk behavior and STI screening and
treatment at baseline. We will return to this issue in the discussion.
As discussed earlier, gel use should reduce the per-contact
infection risk in the treatment group. Using ln again to denote the
proportion of sexual encounters without condoms where the gel
was properly used (i.e., high-risk contacts) and lk the proportion of
encounters with condoms where the gel was properly used (i.e.,
low-risk contacts), the cumulative risk of infection for women in
the treatment group is then equal to
PT~1{f1{p½(1{ha)lnn(1{a)(1{ln)n
(1{eha)lkk(1{ea)(1{lk )kgm
.
In the CAPRISA trial, an average of approximately 70% of the
sex acts were covered by the prescribed two doses of gel, but it is
unknown how adherence was distributed over high- and low-risk
contacts. The results from other microbicide trials that did report
gel adherence over condom and non-condom use contacts
consistently show higher gel adherence levels (i.e., approximately
1.7 times higher) on encounters where condoms are used (e.g.,
[30–32]). We therefore assume that 8 out of the 18 high-risk
contacts (ln~0:44) and 56 out of the 72 low-risk contacts
(lk~0:78) were covered by gel use, giving an overall adherence of
approximately 70% (and a value of 0.78/0.44= 1.77 for the ratio
of the adherence for low- versus high-risk contacts). Using these
estimates, the true method effectiveness (h) can be computed (via a
root-finding algorithm or, more easily, by trial-and-error by
plugging increasing values of h into the equation) that produces the
average cumulative risk of PT~0:085, which corresponds to the
38 HIV infections observed among the 445 women in the
treatment group. One can easily verify that with h~0:32, we
obtain
PT~1{f1{0:32½(1{0:32|0:015)4(1{0:015)5
(1{0:20|0:32|0:015)28(1{0:20|0:015)8g2~0:085 :
The value h~0:32 corresponds to a 68% relative risk reduction,
which, based on the data available and the model assumptions,
can be regarded as the true method effectiveness of the tenofovir
gel (different from the 54% reported by CAPRISA for the high-
adherent women). This per-contact risk reduction needs to be
clearly distinguished from the ratio of the cumulative risks
(RR~PC=PT ), which denotes the relative risk based on the
behavior pattern the women engaged in during the study (i.e., 0.63
in our model, deviating slightly from the 0.61 reported by the
CAPRISA trial due to rounding errors). This application of the
cumulative probability model thus illustrates how the true
effectiveness of an HIV-prevention method can be identified,
accounting for the unique adherence and sexual risk behavior
patterns among trial participants, which can have a notable impact
on trial conclusions.
Effects of Variable Risk Behaviors Patterns on Trial
Outcomes
With the true method effectiveness estimated and the other
parameters as well as the outcomes fitting the CAPRISA data, the
model will now be used to illustrate the impact of various plausible
risk behavior patterns on trial conclusions about the overall
effectiveness of an HIV prevention method and its effectiveness
under variable adherence levels. Note that having to estimate
some parameters in the model to fit the CAPRISA data based on
other prevention trials and meta-analyses affects our confidence in
the estimate of h, but not in any of the principles illustrated.
First, consider the sexual behavioral patterns monogamy (m~1
partner with k~10 protected followed by n~8 unprotected
contacts), serial monogamy (m~2 partners with k~36 protected
and n~9 unprotected contacts per partner), and promiscuity but
with high levels of condom use (m~30 partners with k~3
protected and n~0 unprotected contacts per partner). While we
assume that women with these different behavioral patterns all
have a total of 90 contacts, the relative infection risks are very
different, even when keeping h and adherence constant at the
values calculated earlier. For monogamous women, the
RR~0:81, while for the serial monogamy and promiscuous
behavior patterns, the relative risks are RR~0:63 and RR~0:48,
respectively. Hence, depending on the dominant risk behavior
patterns of women in a trial, very different relative risks may be
observed. The importance of this point should not be underesti-
mated: if the tenofovir gel would have been tested among the
women in the trial by Skoler-Karpoff and colleagues [33], with
somewhat higher coital frequency and lower condom use
percentages, the relative risk would have been between 0.79
(assuming an average of 1 partner) and 0.74 (for 2 partners), and
trial results might very well have indicated that the tenofovir gel is
not effective in preventing HIV.
Besides these plausible sexual behavior patterns, the ratio
between adherence on risky and non-risky encounters impacts the
relative risk. For example, if we were to compare women with
serial monogamy, then 44% adherence for unprotected and 78%
adherence for protected contacts (i.e., ln~0:44 and lk~0:78)
implies a relative risk of RR~0:63. However, the same overall
adherence of 70% could be obtained if we were to assume that
ln~0:00 and lk~0:88 (i.e., 0 out of the 18 high-risk contacts and
63 out of the 72 low-risk contacts covered by gel use) or ln~0:67
and lk~0:71 (i.e., 12 out of the 18 high-risk contacts and 51 out of
the 72 low-risk contacts covered), yielding relative risks of
RR~0:77 and RR~0:57, respectively. In other words, an overall
adherence of 70% can imply very different relative risks depending
on whether gel use is more likely for high- or low-risk contacts.
Finally, not only is there a direct relationship between
adherence and sexual behavior patterns with the relative risk of
infection, also the relationship between adherence and the relative
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risk depends on the behavior pattern of the women. Figures 2 and
3 show how the cumulative relative risk changes as a function of
adherence for high-risk contacts (i.e., ln) for the three different
behavior patterns described earlier if we assume either 100% (i.e.,
lk~1:00) or 50% (i.e., lk~0:50) adherence for low-risk contacts,
respectively. The solid horizontal line drawn at h~0:32 reflects
the per-contact effectiveness (i.e., the true method effectiveness) of
the gel in reducing the infection risk.
Figures 2 and 3 illustrate several points. First of all, an
increasing level of adherence in the treatment group leads to a
cumulative relative risk that approaches h. However, the influence
of adherence clearly depends on the behavior pattern (i.e., the lines
are not parallel). Moreover, the relationship between adherence
and the cumulative relative risk is not necessarily linear. Finally, it
is important to note that even under perfect adherence the
cumulative relative risk does not reach h~0:32, since the
cumulative relative risk also depends on the sexual risk behavior
patterns (a principle illustrated in Figure 1, where the cumulative
relative risk approaches 1 with an increase in coital frequency
regardless of adherence). Therefore, the cumulative relative risk
will essentially always underestimate the true per-contact relative
risk (i.e., true method effectiveness of the gel).
The results from this model and the illustrations based on the
CAPRISA data therefore suggest that (a) neither the overall
observed incidence rate ratio nor the observed ratio among highly
adherent women in a trial reflect the true method effectiveness, (b)
the secondary adherence analyses in PrEP trials oversimplify the
complex interplay between adherence levels and behavior
patterns, and (c) conclusions about whether or not an HIV
prevention methods works can be markedly different in samples
with different behavioral patterns (e.g., higher coital frequency,
more partners, different levels of adherence), regardless of the methods
true effectiveness. This could explain recent apparently contradictory
trial results in this field [2,3,4,5].
Discussion
Curbing the spread of HIV remains one of the most pressing
health issues to date. Microbicides and other biomedical HIV
prevention measures may play an important role in this endeavor.
The CAPRISA trial (and other recent trials examining early
treatment and pre-exposure chemoprophylaxis interventions)
[2,34] may mark a turning point in HIV prevention research.
However, we believe that the analyses conducted in PrEP trials so
far have not accounted for the complex interplay between
adherence, sexual risk behavior patterns, and HIV infection rates.
By developing a cumulative probability model of HIV infection
(e.g., [23–26]) to analyze HIV prevention trial results, and using
data from the CAPRISA trial and several meta-analyses to
illustrate the principles and implications, this paper has shown that
variable risk behavior and adherence patterns in the study sample
are likely to impact the primary trial conclusions about the
efficacy/effectiveness of an HIV prevention measure, as well as the
results of secondary adherence analyses intended to identify the
impact of the gel under poor, intermediate, and optimal use.
Although some of the parameters in our model had to be
estimated, this leaves the principles illustrated unaffected. These
findings have a range of possible implications.
First of all, the cumulative probability model revealed how
adherence on high- versus low-risk contacts, condom use, the
frequency of sexual contacts and the number of partners directly
influence the cumulative relative risk of infection. The effects of
Figures 2. Relative infection risk as a function of adherence for high-risk contacts under the cumulative probability model for three
different behavior patterns (m= number of partners, k = number of contacts per partner with condom use, n= number of contacts
per partner without condom use), assuming a true per-contact relative risk of h~0:32 and 100% adherence for low-risk
contacts.
doi:10.1371/journal.pone.0044029.g002
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variable behavioral patterns on the relative risk of infection can be
substantial, as we illustrated, for example, by comparing the
findings in the CAPRISA trial (i.e., 39% risk reduction) with the
expected risk reduction if women had been somewhat more
sexually active and condom usage rates were lower (i.e., a risk
reduction of 21% to 26%). This finding implies that in HIV
prevention trials where the sexual risk behavior variables are
generally higher (e.g., due to summarizing behavior over longer
follow-up periods or because of the selection of high-risk
individuals), where condom use rates or adherence overall is
lower, or where adherence is proportionally lower on high- versus
low-risk encounters, the observed relative risk reductions will be
smaller (i.e., more biased towards the null-hypothesis) regardless of
the true effectiveness of the prevention method tested. Not only
does this affects how highly trial results are being valued (e.g., trial
implications are rather different when the reported risk reduction
is 54%, 39%, or 21%), but this could also have a notable impact
on the power to detect a significant treatment effect (computations
done but not shown here). Not accounting for these issues could
explain why the CAPRISA results could not be replicated in the
VOICE study (among higher-risk women), or why oral PrEP has
been effective in some studies but not in others [2,3,4,5]. We
therefore recommend researchers of previous trials to redo their
analyses and control for these (time-varying) effect modifiers where
possible, and future trials to start taking these factors into account
when conducting sample size computations. Since the sexual
behavior of the women tends to be strongly impacted by their
participation in the trial, and adherence (ratios) may be unknown
prior to the trial, confirming sample size calculations during early
interim analyses is recommended.
Moreover, since the observed risk reduction is a combination of
sexual behavior, adherence, and the true method effectiveness of
the HIV prevention method tested, the results of a trial in one
setting cannot be directly generalized to other settings where the
target population may have very different risk behavior patterns.
In fact, because of the adherence support, behavioral measure-
ments, participant reimbursements, and the provision of condom
counseling (which appears to be highly effective in all trials we
examined), the behaviors of women participating in microbicide
trials are very different from the behaviors they displayed prior to
the trial (e.g., condom use percentages double, coital frequency
and number of partners decline). Consequently, the risk reductions
observed in trials are not suitable for estimating the actual impact
of the gel on the HIV pandemic if disseminated on a large scale. A
more accurate estimate of the potential impact of the large-scale
implementation of an effective HIV prevention method could be
obtained by fitting a mathematical model similar to the one we
presented in this paper to identify the true method effectiveness
(i.e. the reduction in the per-contact infection risk). This true
method effectiveness can then be combined with ‘real-life’ data on
sexual behavior to model the expected impact of large-scale
implementation for several average adherence and retention levels
for low- and high-risk sexual encounters. These results in turn offer
targets for trials trying to identify the most cost-effective adherence
support programs, targets that may vary considerably depending
on the sexual risk behavior patterns in the at-risk group.
In addition to the primary analyses in microbicide trials,
secondary adherence analyses are important for estimating the
impact of an HIV prevention measure under variable levels of use,
and for estimating the true method effectiveness of a prevention
method. The current findings suggests that the results from such
Figures 3. Relative infection risk as a function of adherence for high-risk contacts under the cumulative probability model for three
different behavior patterns (m= number of partners, k = number of contacts per partner with condom use, n= number of contacts
per partner without condom use), assuming a true per-contact relative risk of h~0:32 and 50% adherence for low-risk
contacts.
doi:10.1371/journal.pone.0044029.g003
Effectiveness of HIV Prevention Methods
PLOS ONE | www.plosone.org 8 August 2012 | Volume 7 | Issue 8 | e44029
adherence analyses need to be reexamined because the relation-
ship between adherence and the observed risk reduction is likely to
be obscured by the sexual behavior patterns in the sample. We
cannot, for example, be certain whether the risk reductions
reported by the CAPIRSA authors for the different adherence
levels that were averaged over high- and low-risk encounters (i.e.,
54%, 38% and 28% for adherence levels of .80%, 50%-80%,
and ,50%, respectively) reflect the changing effectiveness of the
gel as a function of adherence, or whether this relationship is (at
least partially) the result of different sexual behavior patterns
between women with different adherence levels, or because of co-
varying ratios of adherence on high- versus low-risk encounters
(e.g., with lower average adherence, gel use becomes less likely on
high-risk compared with low-risk encounters). In fact, Karim and
colleagues report that ‘‘women with the highest gel adherence
tended to have the lowest coital frequency’’ (pp. 1172) [3], which
could partially explain the larger treatment effects observed among
high adherers.
Finally, the current approach used to identify the true method
effectiveness of an HIV prevention method seems inadequate.
Presently, the observed risk reduction under optimal adherence
(e.g., .80%) seems to be used for that purpose. However, as
shown in this paper, the cumulative relative risk among highly
adherent participants still only reflects the method effectiveness of
an HIV prevention method as applied in a particular sample after
displaying a certain sexual behavior pattern for a particular time
period. Even under 100% adherence, the observed relative risk
will underestimate the per-contact relative infection risk (see
Figure 2). Therefore, the cumulative relative risk is not an inherent
property of the effectiveness of the intervention method itself, but
reflects how well the method works in a particular context. On the
other hand, the per-contact relative risk is a direct reflection of the
true method effectiveness and does not depend on the particular
sample of women included in the trial.
Reservations and limitations
The mathematical model used in the present paper represents a
simplified abstraction of a more complicated reality. We did not,
for example, include whether sexual partners where circumcised
or treated for HIV, or other factors proposed to influence the per-
contact infection risk [e.g., 26, 35], since these data were
unavailable. Moreover, we used the average adherence and sexual
behavior patterns of women in CAPRISA. Ideally, person-level,
time-stamped data would have been available for all of the
variables. However, such data was not available to us nor does it
seem feasible for study authors to collect such detailed informa-
tion. A recent comparison between aggregate- versus individual-
level data on sexual behavior indicated, however, that rather
accurate estimates of HIV risk can be obtained even with relatively
simple aggregate data collection techniques [36].
Applying the model to the CAPRISA trial and estimating the
true method effectiveness was necessarily based on some data
assumptions. For example, the ratio of adherence for low- versus
high-risk encounters had to be based on the findings from three
other trials ([30–32]) that reported this information. If, instead of
assuming a ratio of 1.77 (i.e., 78% adherence for low- and 44% for
high-risk contacts), we assume that adherence was approximately
the same for low- and high-risk contacts (i.e., 12 out of the 18 high-
risk and 51 out of the 72 low-risk contacts covered by the gel), then
we obtain an estimate of h~0:41, a 59% relative risk reduction
per contact. If, on the other hand, we assume a similarly large
deviation in the other direction (i.e., a ratio of 2.4, with 6 out of the
18 high-risk and 51 out of the 72 low-risk contacts covered by the
gel), we obtain an estimate of h~0:26, a 74% risk reduction per
contact. Besides that these points illustrate that adherence ratios
can have a notable impact on conclusions about method
effectiveness, they also illustrate the importance of assessing
behavioral data in HIV prevention trials in great detail. Regarding
the current estimate of h~0:32, it is unlikely that the adherence
ratio in CAPRISA deviated this much from these other studies. In
general, several other sensitivity analyses indicated that the
estimated method effectiveness of the tenofovir microbicide
appears to be a relatively robust finding.
One additional aspect of our analyses with the CAPRISA data
warrants some further discussion. In order to match up the
remarkably high seroconversion rates in the CAPRISA study
(approximately 9.1 cases per 100 women-years in the control
group) with the (low-risk) sexual behavior patterns (i.e., few
partners, high condom use, low coital frequency), a very high per-
contact infection risk (i.e., a~0:015) had to be assumed for non-
condom contacts. This value substantially exceeds the male-to-
female per contact infection risk for low-income countries in the
absence of commercial sex exposure that was recently found in a
meta-analysis (mean [95% CI] 0.003 [0.0014-0.0064]) [18], and so
does the HIV incidence rate when compared with national surveys
in South Africa (1.0–2.2 cases per 100 women-years for 15–
49 year olds) [37]. Three model variables could potentially explain
this finding: (1) sexual behaviors were severely underreported and/
or condom use was severely overreported, (2) the prevalence of
HIV in the population of male partners was much higher, or (3)
the placebo gel increases the risk of infection. Although the first
two of these explanations are plausible, the figures would need to
deviate to such an extent (e.g., 5 times as many partners or 5 times
as many sexual encounters per partner) that an additional
explanation is needed. Possibly, the sexual cleansing practices
that Karim and colleagues observed among the women in the
region substantially increased the per-contact infection risk [38].
However, regardless of the specific value we assume for per-
contact infection risk, the general principles illustrated remain
unchanged.
Conclusions
The current study suggests that sexual behavior and adherence
patterns among participants in HIV prevention studies impact the
relative risk of infection and secondary adherence analyses. Taking
these behaviors into account may improve study design, guide data
collection, help to identify effective prevention methods and the
impact of variable adherence levels, and contribute to resolving
current debates about contradictory HIV prevention trial results
[39].
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